Ex vivo enrichment of PRAME antigen‐specific T cells for adoptive immunotherapy using CD137 activation marker selection

Ex vivo enrichment of PRAME antigen‐specific T cells for adoptive immunotherapy using CD137 activation marker selection

Abstract Objective Adoptive immunotherapy with ex vivo expanded tumor‐specific T cells has potential as anticancer therapy. Preferentially expressed antigen in melanoma (PRAME) is an attractive target overexpressed in several cancers including melanoma and acute myeloid leukaemia (AML), with low exp...

Full description

Bibliographic Details
Main Authors: Koon H Lee, Kavitha Gowrishankar, Janine Street, Helen M McGuire, Fabio Luciani, Brendan Hughes, Mandeep Singh, Leighton E Clancy, David J Gottlieb, Kenneth P Micklethwaite, Emily Blyth
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Clinical & Translational Immunology
Subjects:
adoptive immunotherapy
antigen‐specific T cells
PRAME
preferential expressed antigen in melanoma
Online Access:https://doi.org/10.1002/cti2.1200

Internet

https://doi.org/10.1002/cti2.1200

Similar Items